Dexmedetomidine, an α2-adrenoceptor agonist, is used as a
sedative medication for criticalyl ill patients and is known to exert
neuroprotective effects by direct action on neurons and indirect action on neurons through astrocytes.
Interleukin (IL)-6 plays a key role in
neuroinflammation, which accompanies
infection,
traumatic brain injury,
ischemia,
neurodegenerative disorders, as both a pro-inflammatory
cytokine and an anti-inflammatory
cytokine.
Dexmedetomidine suppresses immune function. However, the effects of
dexmedetomidine on
cytokine synthesis in the central nervous system (CNS) remain elusive. We previously reported that IL-1β stimulates
IL-6 synthesis in the rat C6
glioma cell line through the phosphorylation of p38
mitogen-activated
protein (MAP)
kinase, stress-activated
protein kinase (SAPK)/
c-Jun N-terminal kinase (JNK) and IκB. In the present study, we investigated the effects of
dexmedetomidine on the IL-1β-induced
IL-6 synthesis in C6 cells.
Dexmedetomidine inhibited the IL-1β-stimulated
IL-6 release and
mRNA expression in C6 cells. 8-Bromo-adenosine-3',5'-cyclic monophosphate, but not 8-bromo-guanosine 3',5'-cyclic monophosphate, significantly enhanced the IL-1β-induced
IL-6 release and
mRNA expression. However,
dexmedetomidine failed to affect cAMP accumulation in the cells treated with IL-1β or
forskolin, an activator of
adenylyl cyclase.
Yohimbine, an α2-adrenoceptor antagonist, did not reverse the suppressive effects of
dexmedetomidine on the IL-1β-induced
IL-6 release.
Dexmedetomidine did not affect the IL-1β-induced phosphorylation of
p38 MAP kinase, SAPK/JNK, IκB, nuclear factor (NF)-κB or c-Jun. Our findings strongly suggest that
dexmedetomidine inhibits the IL-1β-induced
IL-6 synthesis independently of the
adenylyl cyclase-cAMP pathway through α2-adrenoceptors in C6
glioma cells. It is possible that
dexmedetomidine may affect the immune system in the CNS by regulating the production of
IL-6.